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penetration into avascular regions of tumours
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Summary The poor blood supply to solid tumours introduces many factors that affect the outcome of chemotherapy, one of which is the
problem of drug delivery to poorly vascularized regions of tumours. Whereas poor drug penetration has been recognized as a contributing
factor to the poor response of many solid tumours, the question of drug penetration through multicell layers has not been thoroughly
addressed, largely because of restrictions imposed upon these studies by the requirement for either radiolabelled or naturally fluorescent
compounds. The aim of this study is to describe modifications made to a recently published assay that broadens the scope forassessing drug
penetration during the early stages of drug development and to characterize the ability of various drugs to penetrate multicell layers. DLD-1
human colon carcinoma cells were cultured on Transwell-COL plastic inserts placed into 24-well culture plates so that a top and bottom
chamber were established, the two chambers being separated by a microporous membrane. Drugs were added to the top chamber at doses
equivalent to peak plasma concentrations in vivo and the rate of appearance of drugs in the bottom chamberdetermined by high-performance
liquid chromatography (HPLC). Both 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine) and 7-[4'-(2-nitroimidazol-1-yl)-butyl]-
theophylline (NITP) rapidly penetrated DLD-1 multicell layers (50.9 ± 12.1 gm thick) with t1,2 values of 1.36 and 2.38 h respectively, whereas
the rate of penetration of 5-aziridino-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] prop-,-en-a-ol (EO9) and doxorubicin through
multicell layers was significantly slower (t1,2 = 4.62 and 13.1 h respectively). Inclusion of dicoumarol increases the rate of E09 penetration,
whereas reducing the oxygen tension to 5% causes a reduction in tirapazamine penetration through multicell layers, suggesting that the
extent of drug metabolism is one factor that determines the rate at which drugs penetrate multicell layers. The fact that E09 does not readily
penetrate a multicell layer, in conjunction with its rapid elimination in vivo (tl,2 < 10 min), suggests that E09 is unlikely to penetrate more than
a few ,um from a blood vessel within its pharmacokinetic lifespan. These results suggest that the failure of E09 in the clinic is due to a
combination of poor drug penetration and rapid elimination in vivo.
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The ultimate objective of any systemic therapy for cancer is to
eradicate all tumour cells whether it is by direct cytotoxicity or by
modifying the malignant phenotype (Schipper et al, 1996). In
order to achieve this objective, it is essential that anti-cancer
agents reach all clonogenic cells within the tumour at the concen-
trations that are required for a therapeutic effect. The blood supply
to many solid tumours is known to be both inadequate and inter-
mittent, resulting in regions of tumours that are chronically and
transiently hypoxic (Coleman, 1988; Vaupel et al, 1989). Hypoxia
by itself, or in conjunction with other features of the tumour
microenvironment such as low extracellular pH and reduced cell
proliferation rates, etc., can adversely affect the efficacy of both
radiotherapy and chemotherapy (Thomlinson and Gray, 1955;
Denekamp, 1986). In terms ofchemotherapy, cytotoxic drugs have
to diffuse from the vascular compartment and penetrate through
several layers of cells in order to reach cells that reside some
distance away from a blood vessel. Drug penetration barriers exist
for a number ofclinically used anti-cancer drugs, and the failure of
drugs to penetrate throughout the tumour within their pharmaco-
kinetic lifespan has been recognized as a contributing factor
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towards the poor response ofmany solid tumours tochemotherapy
(Goldacre and Sylvdn, 1962; Kerr and Kaye, 1987; Durand, 1989;
Simpson-Herren and Noker, 1991). Multicellular spheroids
(Sutherland and Durand, 1976; Sutherland, 1988) have been
instrumental in the study of drug diffusion through multicell
layers, anddrug penetration barriers have been identified fordrugs
such as doxorubicin, methotrexate, m-AMSA, ara-C, vinblastine
and vincristine (Sutherland et al, 1979; West et al, 1980; Wilson et
al, 1981; Nederman and Carlsson, 1984; Erlanson et al, 1992).
Whereas the ability to penetrate several layers ofcells is a desir-
able property of all systemic-based anti-cancer therapies, it is
particularly relevant to a class ofcompounds known as bioreduc-
tive drugs. These compounds are designed to kill cells preferen-
tially within the hypoxic tumour microenvironment (Sartorelli,
1988; Workman and Stratford, 1993) and the ideal bioreductive
drug should be administered as an inactive prodrug that is only
activated under low-oxygen conditions by one or two electron
reductases. An essential prerequisite characteristic for an effective
bioreductive drug is that the parent compound must diffuse
through the aerobic fraction of cells in order to reach the target.
With the exception of early studies using nitroimadazole-based
radiosensitizers (Chapman et al, 1981, 1983; Garrecht and
Chapman, 1983; Franko, 1985; Rasey et al, 1985), relatively few
studies have focused on the ability of bioreductive drugs to pene-
trate through several layers of cells. This is due largely to the fact
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bioreductive indoloquinone compound 5-aziridino-3-hydroxy-
methyl-i -methyl-2-[1H-indole-4,7-dione]prop-4-en-ox-ol (EO9),
which, despite promising activity in preclinical models (Hendriks
et al, 1993), has proved disappointing in the clinic (Pavlidis et al,
1996). Studies demonstrating that spheroids are more resistant
than monolayers to E09 suggest that drug penetration barriers
may exist (Bibby et al, 1993) and this study provides experimental
evidence to support the hypothesis that the failure of E09 in the
clinic is due to poor penetration into tumours, in conjunction with
rapid elimination kinetics in vivo.
MATERIALS AND METHODS
Test compounds
3-Amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine) and7-[4'-
(2-nitroimidazol-1-yl)butyl]-theophylline (NITP) were gifts from
Sanofi Winthrop (USA) and Dr Richard Hodgkiss (Gray
Laboratories, UK) respectively. E09 was supplied by the New
Drug Development Office of the EORTC (European Organization
for the Research and Treatment of Cancer). Doxorubicin was
purchased from Sigma (Sigma Aldrich, Poole, UK). Tirapazamine,
NITP and E09 were dissolved in DMSO and stored at - 20°C.
Doxorubicin was dissolved in sterile water and stored at - 200C.
All chemicals used were of analytical grade (Sigma) and all
solvents were HPLC grade (Fisher Scientific, Loughborough, UK).
Microporous membrane
24-Well plate
Figure 1 Schematic representation of the Transwell apparatus for
assessing drug penetration
Cell culture conditions
DLD-1 human colon carcinoma cells (Dexter et al, 1979) were
routinely maintained at 37°C as monolayer cultures in RPMI-1640
culture medium containing 25 mM HEPES buffer (Life
Technologies, Paisley, UK) supplemented with 10% fetal calf
serum (Life Technologies), sodium pyruvate (1 mm, Life
Technologies,), penicillin-streptomycin (100 IU ml-':100,g ml-',
Life Technologies), L-glutamine (1 mm, Life Technologies).
that compounds have had to be either naturally fluorescent (such
as doxorubicin) or radioactively labelled in order to detect penetra-
tion into cellular masses. In the early stages of drug development,
however, radioactively labelled or fluorescent compounds are
rarely available and, consequently, the question of drug penetra-
tion has not been thoroughly addressed for the majority of
compounds.
Recently, an assay has been developed that has broadened the
scope for studying drug penetration during the early stages of
preclinical drug development (Cowan et al, 1996). The assay is
based upon the ability of drugs to cross a microporous membrane
that supports a multicell layer. Routine analytical techniques [e.g.
high-performance liquid chromatography (HPLC)] can be used to
measure drug (and/or metabolite) concentrations, making the
study ofdrug penetration a feasible proposition for most laborato-
ries involved in preclinical drug development. The principal
objective of this study is to describe and characterize a modified
version of the assay published by Cowan et al (1996) and to illus-
trate the potential significance of this assay by evaluating the
ability of selected bioreductive and standard anti-cancer drugs to
penetrate multicell layers. Particular attention has been paid to the
Growth characteristics of DLD-1 cells in Transwell
culture vessels
A total of 2.5 x 105 cells in 200 ,ul of RPMI-1640 culture medium
was added to the top chamber of Transwell-COL plastic insert
(Figure 1, Corning Costar, High Wycombe, UK). The top and
bottom chambers were separated by a collagen-coated, micro-
porous membrane (pore size 0.4 gm, diameter 6.5 mm, surface
area 0.33 cm2). Transwell vessels were incubated at 37°C for 3 h
to allow cells to attach to the membrane before the addition of2 ml
of RPMI-1640 to the bottom chamber. Cells were incubated at
37°C in an atmosphere containing 5% CO2 for up to 8 days with
daily changes of medium in both upper and lower chambers. At
various time points, Transwell inserts were removed, fixed in
Bouin's fluid for 1 h and washed in 70% ethanol overnight. The
membrane was detached from the plastic insert, embedded in
paraffin wax and sectioned (5 ,um) using a Leitz rotary microtome
(Leica UK, Milton Keynes, UK). Sections were stained with
haematoxylin and eosin according to standard protocols, and the
average thickness of the multicell layer determined by a Seescan
image analyser (Seescan, Cambridge, UK). Three separate
Transwells per time point were sectioned and the thickness ofeach
multicell layer was determined on five sections from each
Transwell (20 measurements per section).
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Figure 2 Growth of DLD-1 multicell layers on Transwell inserts. Each point
represents the mean + standard deviations for > 100 measurements on a
total of five histological sections (three Transwells per time point)
Drug penetration assay
Medium was removed from the top chamber of the Transwell and
replaced with 100pl of medium (phenol red-free RPMI-1640
medium supplemented with 10% fetal calf serum) containing
drugs at doses that represent peak plasma drug concentrations in
vivo (EO9 10 gM, tirapazamine 120 gM, NITP 100 gM and
doxorubicin 10 ,UM; van der Vijgh et al, 1990; Bibby et al, 1993;
Walton and Workman, 1993; Hodgkiss et al, 1995). In all cases,
the final DMSO concentration was < 0.2%. The Transwell was
then inserted into one well of a 24-well plate containing 600 gt of
medium and incubated at 37°C. At various time intervals there-
after, 500,l of medium was removed from the bottom chamber
and added to I ml of acetonitrile, mixed and stored at - 20°C until
required for analysis. The insert was then transferred to a different
well on the culture plate containing 600,l of fresh medium. This
procedure was repeated throughout the duration ofthe experiment.
At all stages of the process, medium in the bottom chamber was
agitated using a small magnetic stirrer. In the case of E09, drug
penetration was assessed on days 1, 4 and 8 ofthe growth curve in
order to determine the relationship between the thickness of the
multicell layer and the rate of penetration. In the case of tirapaza-
mine, NITP and doxorubicin, drug penetration was determined on
day 4 ofthe growth curve. All experiments were repeated indepen-
dently on three occasions. The stability of test compounds under
the experimental conditions used (i.e. tissue culture medium at
37°C for 3 h) was determined according to the procedures
described above.
Sample analysis
Samples were evaporated down to 500 tl under vacuum using a
RC10.10 centrifugal evaporator (Jouan, Ilkeston, UK). A further
Figure 3 Histological sections through DLD-1 multicell layers on days
1 (A), 2 (B), 4 (C), 6 (D) and 8 (E) of the growth curve
100 ,ul of acetonitrile was added to each sample to make it more
compatible with the mobile phases used. Following centrifugation
(7000 g x Omin), E09 and doxorubicin concentrations in the
supernatant were determined by HPLC according to previously
published protocols (Scounides et al, 1984; Kotake et al, 1985;
Phillips et al, 1992). In the case of tirapazamine, a modified
version of the assay described by Robin et al (1995) was
employed, brief details of which are described below. Samples
were separated using a JBondapak (10 gm) phenyl column in a
RCM 8 x 10 radial compression module (Waters, Watford, UK).
The mobile phase was acetonitrile-water (11:89) pumped at a flow
rate of 2.0 ml min-' and tirapazamine was detected at 266 nm.
NITP was analysed using the same methodology as for tirapaza-
mine except that the mobile phase was 30% acetonitrile-water and
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detection was at 272 nm. In all cases, the HPLC apparatus
consisted of a model 510 pump (Waters), 717 autosampler
(Waters), and detection systems were either a model 996 photo-
diode array detector with Millennium software (Waters) or a
Merck/Hitachi F1050 HPLC fluorescence detector (Merck,
Lutterworth, UK).
Data analysis
Drug concentrations in each sample were summated such that a
graph of total drug penetration against time could be plotted. For
example, drug concentrations at time point 1 were added to drug
concentrations at time point 2 in order to obtain the total drug
concentration in the lower chamber at time point 2. Drug concen-
trations in the lower chamber were calculated from the ratio of
peak areas for samples divided by the peak area ofdrug in the top
chamber at t = 0. Drug penetration through the multicellular layer
was assumed to be a first-order process. Half-lives and penetration
rate constants were calculated by standard pharmacokinetic proce-
dures (Rowland and Tozer, 1989), normally used for the absorp-
tion of drug into the plasma from an extravascular site with Ae-Kp
representing the movement of drug through the multicell layer.
Therefore the equation to describe the drug appearing in the
bottom chamber as a function of time is the monoexponential
equation:
C = Ae-K'
where Cl = concentration of drug in lower chamber, A = 100%
penetration andKp = penetration rate conbtant.
Kp is calculated from the per cent penetration vs time data using
the method of residuals and is equivalent to the absorption rate
constant. Penetration half-lives (t,12p) are calculated from the equa-
tion t1,2p =0.693/Kp. Percent penetration was calculated as the drug
concentration measured in lower chamber/drug concentration
expected if all the administered drug penetrated through the
membrane.
Influence of dicumarol on the penetration of E09
DLD-1 cells were cultured in Transwell-COL inserts for 4 days
(thickness ofthe multicell layer was 45 ± 5.2 ,um). E09 was added
to the top chamber at a final concentration of 10gM as described
above in the presence or absence of dicoumarol (200gM). In
studies using dicoumarol, medium in the bottom chamber also
contained dicoumarol (200gM). The change in E09 concentration
in the lower chamber was determined as described above.
Influence of oxygen tension on the rate of penetration
of tirapazamine
DLD-1 cells were cultured in Transwell-COL inserts as described
above (thickness of multicell layer was 50 ± 5.6 im). Culture
plates were then transfered to an incubator supplied with 5%
oxygen, 5% CO2 and 90% nitrogen (BOC, Manchester, UK) for
3 h before the addition of tirapazamine (55 gM, which represents
peak plasma levels in humans, Graham et al, 1997) to the top
chamber. The appearance of tirapazamine in the lower chamber
was determined as a function of time as described above. For the
purpose of comparison, the penetration of tirapazamine through
DLD-1 multicell layers cultured in an atmosphere containing 5%
CO2/95% air was also determined.
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Figure 4 Penetration of doxorubicin (A) and tirapazamine (B) through the
membrane alone (2) and through DLD-1 multicell layers (O, 50.9,m thick).
Each point represents the mean ± standard deviation for three independent
experiments
British Journal ofCancer(1998) 77(12), 2112-2119
i; --T
1
0 CancerResearch Campaign 19982116 RM Phillips etal
RESULTS
Growth characteristics of DLD-1 cells on Transwells
Growth curves for DLD-1 cells are presented in Figure 2. The
thickness of the cell layers increased from 15.2 ± 4.6 gm on day 1
to 78.3 + 10.1 ,Im on day 8 (Figure 2). There was a rapid increase
in the thickness ofcell layers between days 1 and4, after which the
rate of growth of the multicell layer slows down. As multicell
layers increased in thickness, cells growing on or near the
membrane became elongated and polarized, whereas cells further
away from the membrane adopted a flattened appearance (Figure
3). No visible regions ofnecrosis existed (Figure 3) and no binding
of NITP could be detected by antibodies to theophylline
throughout the section, indicating the absence of hypoxic cells
(data not shown).
Penetration of drugs through multicell layers
The penetration oftirapazamine and doxorubicin across Transwell
membranes in the presence and absence of DLD-1 cells (50.9 ±
12.1 ,um thick) is presented in Figure 4. In the absence of cells,
both tirapazamine and doxorubicin rapidly crossed the membrane
with half-lives of 0.092 and 0.178 h respectively (Table 1). In the
presence of DLD- 1 multicell layers, the penetration of tirapaza-
mine through the cell layer was significantly greater than that of
doxorubicin with t12 values of 1.36 and 13.1 h respectively (Table
1). Only the parent compounds were visible on HPLC traces and
no metabolites were detected. Both compounds were stable (< 5%
breakdown) for the duration ofthis experiment. The penetration of
tirapazamine, NITP, E09 and doxorubicin through multicell layers
is presented in Figure 5. Each drug evaluated penetrated through
DLD-1 multicell layers (50 jim thick) at different rates (Figure 5
and Table 1). Half-lives were 1.36, 2.38, 4.62 and 13.1 h for tira-
pazamine, NITP, E09 and doxorubicin respectively (Table 1). No
metabolites were detected. E09 was relatively stable at 37°C in
tissue culture medium at pH 7.5 with a t12 value of 6.5 h (Phillips
et al, 1992).
Influence of the thickness of the multicell layer on the
rate of E09 penetration
Figure 6 describes the penetration of E09 through transwell
membranes in the absence of cells and in the presence of DLD-1
multicell layers of 15.2 jm, 50.9 jim and 78.3 jim thickness. Rates
of drug penetration (Table 2) were inversely proportional to the
thickness of the multicell layer with Kp values (h-') ranging from
1.12 (15.2 jim thick) to 0.030 (78.3 jim thick).
Influence of oxygen tension and dicoumarol on the
penetration of tirapazamine and E09
Reducing the oxygen tension to 5% oxygen causes a significant
reduction in the rate of tirapazamine penetration (Kp = 0.26 h-',
t,,2 = 2.66 h, Table 3) compared with the rate of penetration in an
atmosphere containing 20% oxygen (Kp = 0.489 h-', t12 = 1.42 h,
Table 3). In the case ofE09 (Table 3), the inclusion ofdicoumarol
in both the upper and lower chambers of the Transwell apparatus
results in a modest increase in the rate of drug penetration (t12 =
2.7 ± 0.63 h) compared with the rate of E09 penetration in the
absence ofdicoumarol (t12 = 3.6 ± 0.41 h).
Table 1 Summary of drug penetration data for doxorubicin (DOX), E09,
NITP and tirapazamine (TP) through DLD-1 multicell layers (50.9 gm thick)
No cells Day 4
Kp'h-1' t1,2(h) Kp'h-t' tl,2(h)
DOX 3.90 0.178 0.035 ± 0.025 13.1
E09 3.63 0.191 0.15 ± 0.05 4.62
NITP 13.4 0.052 0.29 ± 0.09 2.38
TP 7.56 0.092 0.51 ± 0.19 1.36
t,12' the time taken for half the initial drug concentration in the top chamber to
cross into the lower chamber; Kp, penetration rate constant.
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Figure 5 Penetration of tirapazamine (O), NITP (O), E09 (0) and
doxorubicin (A) through DLD-1 multicell layers (50.9 gm thick). Each point
represents the mean ± standard deviation for three independent experiments
DISCUSSION
The problem of poor drug delivery to viable cells in avascular
regions of solid tumours has been recognized as a contributing
factor to the lack of activity of currently available anti-cancer
drugs against the majority of solid tumours (Keyes et al, 1985;
Sartorelli, 1988). Although this fact is generally accepted, the
question of drug penetration into cellular masses has not received
the intense investigation it merits, largely because ofpractical and
technical difficulties inherent in the methods used to evaluate drug
penetration. The question of drug penetration is vital for
compounds such as bioreductive drugs but good diffusion
throughout tumours would be a highly desirable characteristic
for any systemic-based therapy of cancer. The assay initially
described by Cowan et al (1996) and modified in this paper is tech-
nically simple and versatile, thereby broadening the scope for
conducting drug penetration studies early on in drug development.
The methodology described in this paper differs from that of
Cowan et al (1996) in several key areas, details ofwhich are outlined
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Figure 6 Penetration of E09 through Transwell membranes in the absence
of cells (A) and in the presence of cell layers that were 15.2 ,um (K), 50.9 gm
(0) and 78.3 ,im (O) thick. Each point represents the mean ± standard
deviation for three independent experiments
below. First, the assay has been miniaturized so that valuable drug
stocks can be conserved. Second, the model described by Cowan et
al (1996) does not mimic the aerobic fraction ofcells as the multicell
layer used contains a central necrotic core. Drugs would have to
diffuse through an aerobic fraction intothe necrotic core andthen out
the other side of the necrotic core and through another aerobic
fraction of cells before crossing the microporous membrane. The
complexity of this model introduces several problems, particularly
as bioreductive drugs, for example, would be activated within the
hypoxic region, leading to anunderestimation ofdrugpenetration. In
our opinion, the key question is whether or not the drug actually
penetrates through the aerobic fraction ofcells as the original, inac-
tive prodrug, and therefore this assay uses multicell layers that
mimic the aerobic fraction. Third, no soft agar has been included in
the upperchamberas described by Cowan et al (1996). Soft agarwas
initially added to the upper chamber to prevent convection currents
but its inclusion significantly reduces the rate of drug penetration
through microporous membranes that have no cells attached.
Finally, standard pharmacokinetic parameters have been applied
to the analysis of drug penetration data as opposed to Fick's
second law of diffusion. In our opinion, the use of pharmaco-
kinetic parameters is more relevant, as diffusion is not the only
mechanism by which drugs cross multicellular layers (Kerr and
Kaye, 1987). In addition, as the rate of penetration into a tumour
will depend upon the concentration of drug in the blood and the
rate ofelimination from the body, it may be possible to predict the
extent of drug penetration into tumours based upon knowledge of
the drug's pharmacokinetics in vivo and the rate of penetration
through multicell layers in vitro. The results of this study demon-
strate that penetration across multicell layers is a first-order
process and the pharmacokinetic parameters generated in vitro
Table 2 Relationship between the rate of E09 penetration and the
thickness of multicell layer
No cells Day 1 Day 4 Day 8
Kp(h-1) 3.63 1.12 ± 0.08 0.150 ± 0.05 0.030± 0.025
t12(h) 0.190 0.618 4.62 23.1
tl,2(min) 11.4 38.4 258.0 1428.0
Distance (,um) 0 15.2 ± 4.6 50.9 ± 12.1 78.3 ± 10.1
t1,2' the time taken for half the initial drug concentration in the top chamber to
cross into the lower chamber; Kp, penetration rate constant.
Table 3 Influence of dicoumarol and oxygen tension on the rate of
penetration of E09 and tirapazamine through DLD-1 multicell layers
E09 Tirapazamine
- dicoumarol + dicoumarol 20% 02 5% 02
t,,2(h) 3.60 ± 0.41 2.70 ± 0.63 1.42 2.66
Kp(h-1) 0.19 + 0.02 0.25 ± 0.05 0.489 0.26
Thickness of 45.0 ± 4.20 45.0 ± 4.20 50.0 ± 5.60 50.0 ± 5.60
multicell layer
(gm)
could be directly compared with pharmacokinetic parameters in
vivo to obtain an indication of whether a drug will reach the
tumour microenvironment within its pharmacokinetic lifespan.
In the case of bioreductive drugs, the question of drug penetra-
tion is paramount as failure of the parent compound to penetrate
through the aerobic fraction oftumourcells into hypoxic regions of
tumours (within the pharmacokinetic lifespan of the drug in vivo)
will severely limit the efficacy ofthe drug. Estimates ofthe aerobic
fraction vary and are difficult to define precisely as gradients of
oxygen tension exist within tumours, the extent ofwhich varies as a
function of distance from a supporting blood vessel (Helminger et
al, 1997). Gradients of oxygen tension have been demonstrated
within the viable rim of multicellular spheroids (Sutherland et al,
1986) and drugs have to penetrate approximately 200-300,m
(depending on the cell line) in order to reach the central necrotic
region. It is reasonable to assume therefore that drugs would have
to penetrate at least 50 ,um from a blood vessel or into a spheroid in
order to reach the target. Using a multicell layer of 50,m thick-
ness, the assay was validated using drugs whose penetration prop-
erties are known. In the case of tirapazamine, for example,
preferential DNA damage to cells in hypoxic regions of squamous
cell carcinoma (SCCVII) tumours was observed using a combina-
tion of cell sorting and comet assays (Olive, 1995). NITP is
detectable in tissues using antibodies raised against theophylline,
and good evidence exists to show that NITP binds preferentially to
cells that reside close to the necrotic regions of mammary CaNT
tumours (Hodgkiss et al, 1995). Both compounds readily penetrate
DLD-1 multicell layers, although penetration of tirapazamine is
more rapid than NITP under standard cell culture conditions
(Figure 5). In contrast to tirapazamine and NITP, significant drug
penetration barriers are known to exist for doxorubicin (Sutherland
et al, 1979) and this is reflected in the poor rate of penetration
through DLD-1 multicell layers presented in Figure 4.
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A number of factors will influence both the delivery of drugs to
tumours and transcellular drug transport, details ofwhich have been
reviewed elsewhere (Kerr and Kaye, 1987). Preliminary studies in
this paper demonstrate that cellular metabolism is one factor that
influences the penetration of drugs accross multicell layers (Table
3). In the presence of dicoumarol, which is a potent inhibitor of
DT-diaphorase, the rate at which E09 penetrates a multicell layer
increases compared with E09 alone. These results suggest that the
penetration of E09 into tumours with high DT-diaphorase activity
may be impaired as a result ofincreased drug metabolism. It should
be stressed that the activity of DT-diaphorase in DLD-1 cells
(546 ± 75 nmol min-' mg-'; Collard et al, 1995) is significantly
higher than the activity ofDT-diaphorase activity in human tumours
(Malkinson et al, 1992), and further studies are warranted to deter-
mine the effect of drug metabolism in cell lines that have a broader
range ofDT-diaphorase activity. In the case oftirapazamine, the rate
ofdrug penetration is dependent upon the oxygen status ofcultures.
As oxygen tension is reduced, the rate ofdrug penetration decreases,
presumably because of increased tirapazamine metabolism (Koch,
1993). It is not known whether drug metabolism is the rate-limiting
step as other factors such as the morphology of cells (i.e. the
presence of tight junctions between cells), pH gradients, physico-
chemical properties of drugs such as lipid solubility, etc. could also
play a role. These questions are beyond the scope of this paper and
are currently under investigation.
Although the identification of the rate-limiting process that
determines drug penetration will give useful information to guide
future drug development, the principal objective of this paper is to
determine not how currently available drugs get there but whether
they do get to the target. As the rate of drug penetration through
cell layers will be both concentration and time dependent, pharma-
cokinetic parameters are likely to play a major role in determining
the extent of drug penetration from the vasculature in vivo. In
mice, both tirapazamine and NITP have plasma t,2P of 26.5 min
and between 20 and 30 min (depending on vehicle and route of
administration) respectively (Workman and Walton, 1993;
Hodgkiss et al, 1995). As both drugs have been shown to either
damage DNA or bind to cells within the hypoxic tumour micro-
environment, the combination of these pharmacokinetic parame-
ters together with the inherent ability to penetrate rapidly through
multicell layers suggests that these characteristics form a good
guideline for predicting whether other drugs will reach the tumour
microenvironment. Other drugs that have similar pharmacokinetic
parameters and drug penetration rates through DLD-1 multicell
layers would be expected to penetrate through several layers of
cells in vivo. In humans the plasma t1/2 value of tirapazamine is
longer (46.6 ± 9.53 min; Graham et al, 1997) than in experimental
models, suggesting that penetration into the hypoxic micro-
environment of solid tumours is likely.
The significance of both pharmacokinetic parameters and drug
penetration properties is illustrated in the case of E09. E09 is a
bioreductive indoloquinone compound that is activated by the
enzyme DT-diaphorase [NAD(P)H:quinone acceptor oxidoreduc-
tase, EC 1.6.99.21 to a DNA-damaging species and is preferen-
tially cytotoxic towards DT-diaphorase-rich cells in vitro under
aerobic conditions (Walton et al, 1991; Robertson et al, 1994;
Smitkamp-Wilms et al, 1996). The compound was selected for
clinical evaluation under the auspices of the EORTC, although no
activity against non-small-cell lung cancer (NSCLC), breast,
colorectal, pancreatic and gastric cancers was reported in phase II
clinical trials (Dirix et al, 1996; Pavlidis et al, 1996). A possible
explanation for the lack ofclinical activity stems from the fact that
E09 does not penetrate multicell layers as efficiently as tirapaza-
mine or NITP (Figure 5). This result, in conjunction with the fact
that E09 is rapidly eliminated from the body in both rodents and
humans, with plasma half-lives of 3 and 10 min respectively
(Workman et al, 1992; Schellens et al, 1994), suggests that thera-
peutic levels of E09 are unlikely to penetrate more than a few
microns from a blood vessel within its pharmacokinetic life span.
Poor drug delivery to tumours may therefore be the major factor in
explaining the disappointing clinical outcome of E09 as opposed
to pharmacodynamic problems. In mice, direct intratumoral injec-
tion of E09 resulted in preferential anti-tumour activity against
DT-diaphorase-rich tumours, suggesting that, if E09 can be effi-
ciently delivered to tumours, it may be possible to exploit the
differences that exist in DT-diaphorase activity in human tumours
(Malkinson et al, 1992; Matthew et al, 1996). In terms of future
drug development, either improving the delivery of E09 or devel-
oping analogues ofE09 that retain the desirable properties ofE09
(i.e. bioactivation by DT-diaphorase) but have better pharmacolog-
ical properties in terms of drug penetration and pharmacokinetics
are two ways ofaddressing the problem (Phillips, 1996).
In conclusion, this study has described and validated an assay
that addresses the critical question of whether or not cytotoxic
drugs are able to penetrate into avascular regions of solid tumours.
Based upon knowledge ofthe rate ofpenetration through multicell
layers and pharmacokinetic parameters in vivo for drugs whose
penetration properties are known (i.e. tirapazamine, NITP and
doxorubicin), it may be possible to predict whether or not novel
compounds are able to penetrate into the tumour microenviron-
ment. It should be stressed, however, that penetration into avas-
cular regions oftumours will not guarantee efficacy, as cells in this
environment are likely to have different pharmacodynamic charac-
teristics from cells that reside close to blood vessels. Nevertheless,
the question ofpenetration into poorly perfused regions oftumours
is important for all systemic-based therapeutic approaches directed
against the cancer itself. With minor modifications to the assay, the
question of whether or not therapeutic approaches such as anti-
sense, gene therapy, monoclonal antibodies or inhibitors of cell
signalling pathways can penetrate into the microenvironment of a
tumour within their pharmacokinetic lifespans can be determined.
The assay described by Cowan et al (1996), together with the
modifications made to the assay described in this paper, therefore
provide a quantitative method for assessing drug penetration
during preclinical anti-cancer ofdrug development.
ABBREVIATIONS
NITP, 7-[4'-(2-nitroimidazol- 1-yl)-butyl]-theophylline; tirapaza-
mine, 3-amino-1, 2,4-benzotriazine 1,4-dioxide; E09, 5-aziridino-3-
hydroxymethyl-I-methyl-2-[ IH-indole-4,7-dione] prop-p-en-wc-ol.
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